Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice

Journal article


Publication Details

Author(s): Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong ACM, Ortiz A, Schaefer F, Torra R, Vanholder R, Wiecek A, Zoccali C, Van Biesen W
Journal: Nephrology Dialysis Transplantation
Publication year: 2016
Volume: 31
Journal issue: 3
Pages range: 337-48
ISSN: 0931-0509


Abstract

Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to provide guidance for making the decision as to which ADPKD patients to treat with tolvaptan. The present position statement includes a series of recommendations resulting in a hierarchical decision algorithm that encompasses a sequence of risk-factor assessments in a descending order of reliability. By examining the best-validated markers first, we aim to identify ADPKD patients who have documented rapid disease progression or are likely to have rapid disease progression. We believe that this procedure offers the best opportunity to select patients who are most likely to benefit from tolvaptan, thus improving the benefit-to-risk ratio and cost-effectiveness of this treatment. It is important to emphasize that the decision to initiate treatment requires the consideration of many factors besides eligibility, such as contraindications, potential adverse events, as well as patient motivation and lifestyle factors, and requires shared decision-making with the patient.


FAU Authors / FAU Editors

Eckardt, Kai-Uwe Prof. Dr. med.
Medizinische Klinik 4 - Nephrologie und Hypertensiologie


External institutions
Aarhus University Hospital / Aarhus Universitetshospital
Autonomous University of Barcelona (UAB) / Universitat Autònoma de Barcelona
Azienda Ospedaliera "Bianchi Melacrino Morelli", Reggio Calabria
Centre hospitalier universitaire de Brest (CHRU Brest)
Hacettepe University
Hôpital Ambroise-Paré
Julius-Maximilians-Universität Würzburg
Medical University of Silesia in Katowice / Śląski Uniwersytet Medyczny w Katowicach (SUM)
Ospedale Pediatrico Bambino Gesu
Seconda Universita degli Studi di Napoli (SUN)
Spitalul Clinic Doctor C.I. Parhon
Universidad Autónoma de Madrid (UAM)
Universität Köln
Universitätsklinikum Heidelberg
Universität Zürich (UZH)
University Hospital Ghent
University of Groningen / Rijksuniversiteit Groningen
University of Paris 5 - René Descartes / Université Paris V René Descartes
University of Sheffield


How to cite

APA:
Gansevoort, R.T., Arici, M., Benzing, T., Birn, H., Capasso, G., Covic, A.,... Van Biesen, W. (2016). Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 31(3), 337-48. https://dx.doi.org/10.1093/ndt/gfv456

MLA:
Gansevoort, Ron T., et al. "Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice." Nephrology Dialysis Transplantation 31.3 (2016): 337-48.

BibTeX: 

Last updated on 2018-07-10 at 02:55